VitaDAO, a community-owned project focused on longevity research, has launched its first biotech company called Matrix Biosciences. The project, backed by Pfizer Ventures and Shine Capital, aims to develop groundbreaking treatments for cancer and aging-related disorders. Matrix Biosciences has received an initial funding of $300,000 from VitaDAO, with more funding expected through IP-NFT fractionalization in early 2024. The VitaDAO ecosystem relies on the VITA token for governance and rewarding investors. The VITA token has seen a 72% increase in value year-to-date and has a liquidity of over $3 million. The launch of Matrix Biosciences is seen as a significant step forward in advancing the development of innovative treatments in an area that has traditionally lacked an established path.

This News Article was automatically generated by Bob the Bot (AI)

Information	Details
Geography	Europe
Countries	🇺🇸
Sentiment	neutral
Relevance Score	0
People	Vera Gurbunova
Companies	University of Rochester’s Aging Research Center, Shine Capital, eToro, VitaDAO, Matrix Biosciences, Pfizer Ventures, Coinbase, Coingecko
Currencies	None
Securities	None